Insulin-like growth factor-1 and chronic kidney disease in patients with type 2 diabetes mellitus

Article Sidebar

PDF (Русский)
DOI: https://doi.org/10.22141/2224-0721.15.1.2019.158685
Keywords:
type 2 diabetes mellitus, chronic kidney disease, insulin-like growth factor-1

Main Article Content

O.N. Vasilkova
Homel State Medical University, Homel, the Republic of Belarus
T.V. Mokhort
Belarus State Medical University, Minsk, the Republic of Belarus
E.P. Naumenko
Republic Research and Practical Centre of Radiation Medicine and Ecology, Homel, Republic of Belarus
L.E. Korotayeva
Republic Research and Practical Centre of Radiation Medicine and Ecology, Homel, Republic of Belarus
N.A. Filiptsova
Republic Research and Practical Centre of Radiation Medicine and Ecology, Homel, Republic of Belarus

Abstract

Background. Diabetes mellitus (DM) and chronic kidney disease (CKD) are two major medical and socio­economic problems of recent years that the world community has faced in the context of a chronic disease pandemic. CKH leads not only to the development of terminal renal failure, which requires the application of hemodialysis and kidney transplantation, but also to complex metabolic and hormonal disorders in the axis of growth hormone (GH) — insulin­like growth factor (IGF), binding protein (IGFBP) (GH — IGF — IFRBP). The purpose of the study was to evaluate the relationship between serum IGF­1 levels and glomerular filtration rate (GFR) in patients with type 2 DM. Materials and methods. The study involved 150 patients with type 2 DM, the age range of 23 to 86 years. The control group consisted of 57 patients without DM, matched by age and sex with the basic group. In the study, patients with type 2 DM were classified into three subgroups, depending on the stage of albuminuria: the first subgroup consisted of 38 persons with normalbuminuria, the second subgroup included 79 patients with microalbuminuria, the third subgroup consisted of 33 patients with proteinuria. Results. The patients with normal albuminuria did not differ in the level of total cholesterol from the patients in the control group, but the patients with type 2 DM with microalbuminuria and proteinuria had higher values of total cholesterol. By the level of triglycerides, the differences were already noticeable at the stage of normalbuminuria: the patients with type 2 DM had higher levels of triglycerides compared with the control group. The IGF­1 level elevated with increased urinary protein excretion. Correlation analysis showed a significant negative correlation between IGF­1 and GFR and positive one with albumin/creatinine levels. The probability of having GFR < 50 ml/min/1.73 m2 grew with an increase in IGF­1 levels. Conclusions. The elevated levels of IGF­1 and reduced levels of GFR in patients with type 2 DM were found to be associated. Further research is needed to clarify the pathogenetic mechanisms of this interaction.

Article Details

How to Cite
Vasilkova, O., T. Mokhort, E. Naumenko, L. Korotayeva, and N. Filiptsova. “Insulin-Like Growth Factor-1 and Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 15, no. 1, Apr. 2019, pp. 3-9, doi:10.22141/2224-0721.15.1.2019.158685.
Issue
Vol. 15 No. 1 (2019)
Section
Original Researches
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our edition uses the copyright terms of Creative Commons for open access journals.

Authors, who are published in this journal, agree with the following terms:

  1. The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
  2. Directing  the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
  3. The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
  4. The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
  5. The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
  6. The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.

References

National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266.

Wheatcroft SB, Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metab. 2009;20(4):153-62. doi: 10.1016/j.tem.2009.01.002.

Ruan W, Lai M. Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome? Acta Diabetol. 2010;47(1):5-14. doi: 10.1007/s00592-009-0142-3.

Atamer A, Ecder SA, Akkus Z, et al. Relationship between leptin, insulin resistance, insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in patients with chronic kidney disease. J Int Med Res. 2008 May-Jun;36(3):522-8.

Teppala S, Shankar A, Sabanayagam C. Association between IGF-1 and chronic kidney disease among US adults. Clin Exp Nephrol. 2010 Oct;14(5):440-4. doi: 10.1007/s10157-010-0307-y.

Tönshoff B, Blum WF, Mehls O. Derangements of the somatotropic hormone axis in chronic renal failure. Kidney Int Suppl. 1997 Mar;58:S106-13.

Carrero JJ, Chmielewski M, Axelsson J, et al. Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. Clin Nutr. 2008 Aug;27(4):557-64. doi: 10.1016/j.clnu.2008.04.007.

Correa PN, Axelrad AA. Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium: role of insulin‐like growth factor 1. Blood. 1991 Dec 1;78(11):2823-33.

Zapf J, Froesch ER. Insulin-like growth factors/somatomedins: Structure, secretion, biological actions and physiological role. Horm Res. 1986;24(2-3):121-30. doi: 10.1159/000180551.

Frystyk J, Ivarsen P, Skjaerbaek C, Flyvbjerg A, Pedersen EB, Orskov H. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int. 1999 Dec;56(6):2076-84. doi: 10.1046/j.1523-1755.1999.00798.x.

Iglesias P, Diez JJ, Fernandez-Reyes MJ, et al. Growth hormone, IGF-I and its binding proteins (IGFBP-1 and −3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis. Clin Endocrinol (Oxf). 2004 Jun;60(6):741-9. doi: 10.1111/j.1365-2265.2004.02049.x.

Jehle PM, Ostertag A, Schulten K, et al. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. Kidney Int. 2000 Feb;57(2):423-36. doi: 10.1046/j.1523-1755.2000.00862.x.

Mahesh S, Kaskel F. Growth hormone axis in chronic kidney disease. Pediatr Nephrol. 2008 Jan;23(1):41-8. doi: 10.1007/s00467-007-0527-x.

Ballmer PE, McNurlan MA, Hulter HN, Anderson SE, Garlick PJ, Krapf R. Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans. J Clin Invest. 1995 Jan;95(1):39-45. doi: 10.1172/JCI117668.

Schaefer F, Veldhuis JD, Stanhope R, Jones J, Scharer K. Alterations in growth hormone secretion and clearance in peripubertal boys with chronic renal failure and after renal transplantation. Cooperative Study Group of Pubertal development in Chronic Renal Failure. J Clin Endocrinol Metab. 1994 Jun;78(6):1298-306. doi: 10.1210/jcem.78.6.8200929.

Coleman ME, DeMayo F, Yin KC, et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem. 1995 May 19;270(20):12109-16.

Roestenberg P, van Nieuwenhoven FA, Joles JA, et al. Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol Renal Physiol. 2006 Jun;290(6):F1344-54. doi: 10.1152/ajprenal.00174.2005.

Wang S, Denichilo M, Brubaker C, Hirschberg R. Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int. 2001 Jul;60(1):96-105. doi: 10.1046/j.1523-1755.2001.00776.x.

Didushko OM, Herych RP, Cherniavska IV, Yatsyshyn RI, Pankiv VI. Influence of the complex treatment of hypothyroidism on the leptin level in patients with primary hypothyroidism. World of Medicine and Biology. 2018;3(65):59-63. doi: 10.26724/2079-8334-2018-3-65-59-63.

Guha M, Xu ZG, Tung D, Lanting L, Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 2007 Oct;21(12):3355-68. doi: 10.1096/fj.06-6713com.

Most read articles by the same author(s)